WO2012054523A3 - Chemosensory receptor ligand-based therapies - Google Patents
Chemosensory receptor ligand-based therapies Download PDFInfo
- Publication number
- WO2012054523A3 WO2012054523A3 PCT/US2011/056766 US2011056766W WO2012054523A3 WO 2012054523 A3 WO2012054523 A3 WO 2012054523A3 US 2011056766 W US2011056766 W US 2011056766W WO 2012054523 A3 WO2012054523 A3 WO 2012054523A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor ligand
- chemosensory receptor
- total
- based therapies
- pyy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013535013A JP2013540156A (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand based therapy |
AU2011317140A AU2011317140A1 (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
KR1020137012695A KR20140114736A (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
EP11835018.0A EP2630491A4 (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
CA2815024A CA2815024A1 (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
BR112013009635A BR112013009635A2 (en) | 2010-10-19 | 2011-10-18 | chemosensory receptor ligand-based therapies |
CN201180061007.9A CN104220875A (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
SG2013029053A SG189444A1 (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
MX2013004364A MX2013004364A (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies. |
EA201370099A EA201370099A1 (en) | 2010-10-19 | 2011-10-18 | THERAPY ON THE BASIS OF LIGANDS OF CHEMOSENSOR RECEPTORS |
IL225845A IL225845A0 (en) | 2010-10-19 | 2013-04-18 | Chemosensory receptor ligand-based therapies |
ZA2013/03335A ZA201303335B (en) | 2010-10-19 | 2013-05-08 | Chemosensory receptor ligand-based therapies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39471610P | 2010-10-19 | 2010-10-19 | |
US61/394,716 | 2010-10-19 | ||
US201161430914P | 2011-01-07 | 2011-01-07 | |
US61/430,914 | 2011-01-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012054523A2 WO2012054523A2 (en) | 2012-04-26 |
WO2012054523A3 true WO2012054523A3 (en) | 2012-10-04 |
Family
ID=45934655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/056766 WO2012054523A2 (en) | 2010-10-19 | 2011-10-18 | Chemosensory receptor ligand-based therapies |
Country Status (15)
Country | Link |
---|---|
US (1) | US9486463B2 (en) |
EP (1) | EP2630491A4 (en) |
JP (1) | JP2013540156A (en) |
KR (1) | KR20140114736A (en) |
CN (1) | CN104220875A (en) |
AU (1) | AU2011317140A1 (en) |
BR (1) | BR112013009635A2 (en) |
CA (1) | CA2815024A1 (en) |
CL (1) | CL2013001085A1 (en) |
EA (1) | EA201370099A1 (en) |
IL (1) | IL225845A0 (en) |
MX (1) | MX2013004364A (en) |
SG (1) | SG189444A1 (en) |
WO (1) | WO2012054523A2 (en) |
ZA (1) | ZA201303335B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2629773A2 (en) * | 2010-10-19 | 2013-08-28 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
ES2832773T3 (en) | 2012-01-06 | 2021-06-11 | Anji Pharma Us Llc | Biguanide compositions and methods of treatment of metabolic disorders |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
CN104684889A (en) * | 2012-07-10 | 2015-06-03 | 西蒂斯制药有限责任公司 | Tri-salt form of metformin |
JP6180722B2 (en) * | 2012-10-31 | 2017-08-16 | キリンビバレッジ株式会社 | Taste improver of triterpene or its glycoside |
WO2014090512A1 (en) | 2012-12-13 | 2014-06-19 | Unilever N.V. | An edible composition |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
SG10201912392SA (en) * | 2015-07-27 | 2020-02-27 | Suntory Holdings Ltd | Composition containing cyclic dipeptide and sweetening agent |
US20190224214A1 (en) * | 2016-08-16 | 2019-07-25 | Syracuse University | Human ghrelin o-acyltransferase inhibitors |
US20190382462A1 (en) * | 2017-01-13 | 2019-12-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
CA3087077A1 (en) * | 2018-01-09 | 2019-07-18 | Gila Therapeutics, Inc. | Compositions and methods for treating metabolic diseases |
CN111302942B (en) * | 2020-04-09 | 2022-03-01 | 中国热带农业科学院热带生物技术研究所 | Compound with PTP1B inhibitory activity and application thereof |
CN113599382B (en) * | 2021-08-20 | 2023-01-03 | 兰州大学 | Application of quinoline derivatives in preparation of medicines for treating diabetes and complications thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5159928A (en) * | 1989-11-22 | 1992-11-03 | William Keppel | Method and apparatus for measuring and controlling the level of hormones in an animal circulatory system |
WO2003057235A2 (en) * | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
US7396809B1 (en) * | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
US20080306093A1 (en) * | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US20090181887A1 (en) * | 2005-09-08 | 2009-07-16 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS58403B2 (en) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L- Ascorbine Sanseizaino Seizouhou |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5825980B2 (en) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | Cyclic nucleotide quantification method |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS62195323A (en) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | Gastric resident particle |
US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP3249147B2 (en) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
CA2106847A1 (en) | 1991-04-05 | 1992-10-06 | Linda B. Buck | Odorant receptors and uses thereof |
DE69206993T2 (en) | 1991-07-19 | 1996-05-30 | Uniroyal Chem Co Inc | COMPOSITIONS FOR USING FILMS ON SEED |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
DE69322077T2 (en) | 1992-03-25 | 1999-04-08 | Depomed Inc | ORAL PHARMACEUTICAL FORMS BASED ON HYDROXYETHYL CELLULOSE WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES |
US5322697A (en) | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2704146B1 (en) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules of acetylsalicylic acid with controlled release. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
IL108205A0 (en) | 1993-12-28 | 1994-04-12 | Yeda Res & Dev | Olfactory genes and receptors |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
IT1270216B (en) | 1994-06-14 | 1997-04-29 | Recordati Chem Pharm | METHOD OF STABILIZATION OF BIOLOGICALLY ACTIVE COMPOUNDS BY MICROGRANULES COVERED SUSPENDABLE IN FOOD FLUIDS |
ES2100142T3 (en) | 1994-07-08 | 2002-03-01 | Astrazeneca Ab | DOSAGE FORM IN TABLETS I CONSTITUTED BY MULTIPLE UNITS. |
FR2725623A1 (en) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
WO1997017444A2 (en) | 1995-11-09 | 1997-05-15 | Johns Hopkins University School Of Medicine | Novel sperm receptors |
CN1125574A (en) | 1995-11-10 | 1996-07-03 | 邵洪 | Enteric-soluble glutamine |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5874243A (en) | 1997-03-28 | 1999-02-23 | Smithkline Beecham Corporation | OLRCC15 receptor |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
ES2248908T7 (en) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs |
JP2001527023A (en) | 1997-08-11 | 2001-12-25 | アルザ・コーポレーション | Extended release active dosage form adapted for gastric retention |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
EP1091440B1 (en) | 1998-05-29 | 2010-06-02 | JGC Catalysts and Chemicals Ltd. | Method of manufacturing photoelectric cell |
FR2780405B1 (en) | 1998-06-25 | 2001-12-28 | Centre Nat Rech Scient | NOVEL OLFACTORY RECEPTORS AND USES THEREOF |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
GB2354761A (en) | 1999-09-28 | 2001-04-04 | British Sugar Plc | Preparation of benzoyloxy acetic acid derivatives |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
EP1125507A1 (en) | 2000-02-15 | 2001-08-22 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Inulin products with improved nutritional properties |
AU5125801A (en) | 2000-04-07 | 2001-10-23 | Senomyx Inc | T2r taste receptors and genes encoding same |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
DE60121981D1 (en) | 2000-10-25 | 2006-09-14 | Metcon Medicin Ab | COMPOSITION FOR TREATING BLOOD SUGAR EXCHANGE DISORDERS AND METHOD FOR THE PRODUCTION THEREOF |
US6955887B2 (en) | 2001-03-30 | 2005-10-18 | Senomyx, Inc. | Use of T1R hetero-oligomeric taste receptor to screen for compounds that modulate taste signaling |
US8030008B2 (en) * | 2001-04-05 | 2011-10-04 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
JP4744081B2 (en) | 2001-08-31 | 2011-08-10 | ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー | Method for treating disorders using plant extracts |
DE10226203B4 (en) | 2002-06-13 | 2008-04-03 | Südzucker AG Mannheim/Ochsenfurt | Condensed Palatinose, process for its preparation and its use |
CA2490142A1 (en) | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
JP2006528883A (en) | 2003-05-28 | 2006-12-28 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Foods that enhance satiety |
ES2337466T3 (en) | 2003-05-28 | 2010-04-26 | Unilever N.V. | POTENTIAL FOOD PRODUCTS OF THE SACIEDAD. |
US20050038415A1 (en) | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
US20050244810A1 (en) | 2003-09-29 | 2005-11-03 | Egan Josephine M | Taste signaling in gastrointestinal cells |
CA2542547A1 (en) | 2003-10-16 | 2005-05-26 | Daniele Piomelli | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
CA2555921A1 (en) | 2004-02-13 | 2005-09-15 | Nod Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of making and using same |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
ATE439140T1 (en) | 2005-03-31 | 2009-08-15 | Amylin Pharmaceuticals Inc | AMYLIN AND AMYLIN AGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES AND DISORDERS |
JP2008540437A (en) | 2005-05-03 | 2008-11-20 | ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド | Controlled release formulation containing quinine |
US20090170949A1 (en) | 2006-01-25 | 2009-07-02 | Soraya Shirazi-Beechey | Method To Control Body Weight |
US7629134B2 (en) | 2006-07-10 | 2009-12-08 | Duke University | Sour taste receptor compositions and methods |
US20100093861A1 (en) | 2006-09-15 | 2010-04-15 | Stevia Aps | Treatment of insulin resistance or diseases associated with insulin resistance |
US20080107787A1 (en) | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
CN100490789C (en) | 2006-12-22 | 2009-05-27 | 北京亚东生物制药有限公司 | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof |
KR20120030570A (en) * | 2007-04-03 | 2012-03-28 | 미쓰비시 타나베 파마 코퍼레이션 | Combined use of dipeptidyl peptidase iv inhibitor compound and sweetener |
US20080274215A1 (en) | 2007-05-03 | 2008-11-06 | Northern Holdings Inc. | Composition for treatment of cold and flu |
US20080306076A1 (en) | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US20080305500A1 (en) * | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Novel cell-based assays for identifying enhancers or inhibitors of t1r taste receptors (t1r2/t1r3 sweet) and umami (t1r1/t1r3 umami) taste receptors |
US20080311192A1 (en) | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
EP2197433A4 (en) * | 2007-08-20 | 2010-09-08 | Sinai School Medicine | Regulating glp-1 and sglt-1 in gastrointestinal cells |
WO2009049105A2 (en) | 2007-10-09 | 2009-04-16 | Gelesis, Inc. | Methods for inducing satiation |
US8063250B2 (en) | 2007-11-26 | 2011-11-22 | Teva Pharmaceutical Industries, Ltd. | Crystal forms of O-desmethylvenlafaxine fumarate |
WO2010027498A2 (en) * | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
MX2011010192A (en) | 2009-04-03 | 2011-10-17 | Dms Ip Assets B V | Satiety-inducing composition. |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
AU2010239311B2 (en) | 2009-04-20 | 2014-05-22 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
DE102009027744A1 (en) | 2009-07-15 | 2011-01-20 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Precursor compounds of sweet receptor antagonists for the prevention or treatment of diseases |
US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
CN103068380A (en) * | 2010-06-17 | 2013-04-24 | 加州理工学院 | Methods and systems for modulating hormones and related methods, agents and compositions |
AU2012223528A1 (en) | 2011-03-02 | 2013-10-24 | Joseph M. Fayad | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection |
-
2011
- 2011-10-18 CA CA2815024A patent/CA2815024A1/en not_active Abandoned
- 2011-10-18 EP EP11835018.0A patent/EP2630491A4/en not_active Withdrawn
- 2011-10-18 SG SG2013029053A patent/SG189444A1/en unknown
- 2011-10-18 CN CN201180061007.9A patent/CN104220875A/en active Pending
- 2011-10-18 MX MX2013004364A patent/MX2013004364A/en not_active Application Discontinuation
- 2011-10-18 EA EA201370099A patent/EA201370099A1/en unknown
- 2011-10-18 BR BR112013009635A patent/BR112013009635A2/en not_active IP Right Cessation
- 2011-10-18 JP JP2013535013A patent/JP2013540156A/en active Pending
- 2011-10-18 AU AU2011317140A patent/AU2011317140A1/en not_active Abandoned
- 2011-10-18 WO PCT/US2011/056766 patent/WO2012054523A2/en active Application Filing
- 2011-10-18 US US13/276,177 patent/US9486463B2/en active Active
- 2011-10-18 KR KR1020137012695A patent/KR20140114736A/en not_active Application Discontinuation
-
2013
- 2013-04-18 IL IL225845A patent/IL225845A0/en unknown
- 2013-04-19 CL CL2013001085A patent/CL2013001085A1/en unknown
- 2013-05-08 ZA ZA2013/03335A patent/ZA201303335B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5159928A (en) * | 1989-11-22 | 1992-11-03 | William Keppel | Method and apparatus for measuring and controlling the level of hormones in an animal circulatory system |
US7396809B1 (en) * | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
WO2003057235A2 (en) * | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
US20090181887A1 (en) * | 2005-09-08 | 2009-07-16 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
US20080306093A1 (en) * | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
Also Published As
Publication number | Publication date |
---|---|
EP2630491A2 (en) | 2013-08-28 |
US20120094942A1 (en) | 2012-04-19 |
ZA201303335B (en) | 2015-10-28 |
CN104220875A (en) | 2014-12-17 |
AU2011317140A1 (en) | 2013-05-30 |
MX2013004364A (en) | 2013-07-02 |
CA2815024A1 (en) | 2012-04-26 |
IL225845A0 (en) | 2013-07-31 |
KR20140114736A (en) | 2014-09-29 |
EP2630491A4 (en) | 2014-08-27 |
SG189444A1 (en) | 2013-05-31 |
EA201370099A1 (en) | 2013-11-29 |
WO2012054523A2 (en) | 2012-04-26 |
US9486463B2 (en) | 2016-11-08 |
JP2013540156A (en) | 2013-10-31 |
BR112013009635A2 (en) | 2016-07-12 |
CL2013001085A1 (en) | 2014-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012054523A3 (en) | Chemosensory receptor ligand-based therapies | |
PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
AR084558A1 (en) | METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) / PEPTIDO-1 SIMILAR TO GLUCAGON (GLP-1) | |
NZ727871A (en) | Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist | |
WO2007124461A8 (en) | Glp-1 compounds | |
MX362503B (en) | Lixisenatide as add-on therapy to basal insulin in type 2 diabetes. | |
MY181539A (en) | Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
WO2014152460A3 (en) | Prodrugs with prolonged action | |
WO2012169798A3 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
WO2013123492A3 (en) | Glucose-responsive microgels for closed loop insulin delivery | |
MX336209B (en) | Delivery of dry formulations of octreotide. | |
MX336657B (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients. | |
MX362527B (en) | Lixisenatide and metformin for treatment of diabetes type 2. | |
PH12017501662A1 (en) | Treatment type 2 diabetes mellitus patients | |
WO2009076413A3 (en) | Methods, devices and compositions for controlled drug delivery to injured myocardium | |
이우제 | Future Drug Targets for Type 2 Diabetes | |
UA80570U (en) | Method for treating purulonecrotic processes in diabetes mellitus | |
Cho | What’s new in the incretin-based therapy? | |
CAI | Dipeptidyl peptidase IV inhibitors: a new class of oral agents for treatment of type 2 diabetes mellitus | |
LeRoith | Insulin therapy. Foreword | |
UA57509U (en) | Method for treating hyperhomocysteinuria in patients with ischemic heart disease with concomitant diabetes mellitus type 2 | |
Barroso-Sousa | Foot pain, ocular pain, asthenia: case report | |
Kellogg | Experiencing NCORE as Faculty/Staff: A Roundtable Discussion | |
TH1601007180A (en) | Constituents for the treatment of diabetes, which includes insulin and a dual agent of GLP-1 / Glucagon | |
UA76937U (en) | method for surgical treatment of acute necrotic pancreatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11835018 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2815024 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013535013 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/004364 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011835018 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011835018 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137012695 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201370099 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2011317140 Country of ref document: AU Date of ref document: 20111018 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013009635 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013009635 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130419 |